KOPS - The Institutional Repository of the University of Konstanz

PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy

PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy

Cite This

Files in this item

Checksum: MD5:c7ad408f868e35ad5603169133eaf956

KOERNER, Julia, Dennis HORVATH, Valerie L. HERRMANN, Anna MACKERRACHER, Bruno GANDER, Hideo YAGITA, Jacques ROHAYEM, Marcus GROETTRUP, 2021. PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. In: Nature Communications. Nature Publishing Group. 12(1), 2935. eISSN 2041-1723. Available under: doi: 10.1038/s41467-021-23244-3

@article{Koerner2021PLGAp-53746, title={PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy}, year={2021}, doi={10.1038/s41467-021-23244-3}, number={1}, volume={12}, journal={Nature Communications}, author={Koerner, Julia and Horvath, Dennis and Herrmann, Valerie L. and MacKerracher, Anna and Gander, Bruno and Yagita, Hideo and Rohayem, Jacques and Groettrup, Marcus}, note={Article Number: 2935} }

<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/53746"> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/43615"/> <dc:contributor>MacKerracher, Anna</dc:contributor> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-05-25T13:35:25Z</dcterms:available> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/43615"/> <dc:creator>Horvath, Dennis</dc:creator> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-05-25T13:35:25Z</dc:date> <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/53746/1/Koerner_2-qbxph5qm1r8w2.pdf"/> <dc:contributor>Yagita, Hideo</dc:contributor> <dcterms:abstract xml:lang="eng">With emerging supremacy, cancer immunotherapy has evolved as a promising therapeutic modality compared to conventional antitumor therapies. Cancer immunotherapy composed of biodegradable poly(lactic-co-glycolic acid) (PLGA) particles containing antigens and toll-like receptor ligands induces vigorous antitumor immune responses in vivo. Here, we demonstrate the supreme adjuvant effect of the recently developed and pharmaceutically defined double-stranded (ds)RNA adjuvant Riboxxim especially when incorporated into PLGA particles. Encapsulation of Riboxxim together with antigens potently activates murine and human dendritic cells, and elevated tumor-specific CD8+ T cell responses are superior to those obtained using classical dsRNA analogues. This PLGA particle vaccine affords primary tumor growth retardation, prevention of metastases, and prolonged survival in preclinical tumor models. Its advantageous therapeutic potency was further enhanced by immune checkpoint blockade that resulted in reinvigoration of cytotoxic T lymphocyte responses and tumor ablation. Thus, combining immune checkpoint blockade with immunotherapy based on Riboxxim-bearing PLGA particles strongly increases its efficacy.</dcterms:abstract> <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/> <dc:contributor>Koerner, Julia</dc:contributor> <dc:creator>MacKerracher, Anna</dc:creator> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dc:creator>Gander, Bruno</dc:creator> <dc:contributor>Gander, Bruno</dc:contributor> <dcterms:title>PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy</dcterms:title> <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/53746/1/Koerner_2-qbxph5qm1r8w2.pdf"/> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <dc:contributor>Rohayem, Jacques</dc:contributor> <dc:contributor>Herrmann, Valerie L.</dc:contributor> <dc:creator>Groettrup, Marcus</dc:creator> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/53746"/> <dc:rights>Attribution 4.0 International</dc:rights> <dc:creator>Rohayem, Jacques</dc:creator> <dc:language>eng</dc:language> <dc:creator>Yagita, Hideo</dc:creator> <dc:contributor>Horvath, Dennis</dc:contributor> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:creator>Koerner, Julia</dc:creator> <dc:contributor>Groettrup, Marcus</dc:contributor> <dc:creator>Herrmann, Valerie L.</dc:creator> <dcterms:issued>2021</dcterms:issued> </rdf:Description> </rdf:RDF>

Downloads since May 25, 2021 (Information about access statistics)

Koerner_2-qbxph5qm1r8w2.pdf 94

This item appears in the following Collection(s)

Attribution 4.0 International Except where otherwise noted, this item's license is described as Attribution 4.0 International

Search KOPS


Browse

My Account